5 Key Takeaways
-
1
Durability in treatment for neovascular age-related macular degeneration (nAMD) is a primary focus of gene therapy development.
-
2
The ixoberogene soroparvovec (Ixo-vec) program shows promising long-term follow-up with stable visual acuity and reduced injection burden.
-
3
The 4D-150 therapy, designed to express an anti-VEGF protein and VEGF-C inhibitor, has shown durable benefits in broader patient populations.
-
4
Safety concerns regarding intraocular inflammation have improved with evolving dose selection and steroid prophylaxis strategies.
-
5
Real-world physician behavior will significantly influence the practical definition of treatment durability in gene therapy.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.